R. C. V. Waardenburg

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

J. Schellens, J. Beijnen, D. Pluim, 2004, Cancer Chemotherapy and Pharmacology.

Advances in Brief Overexpression of the BCRP / MXR / ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line 1

J. Schellens, D. Pluim, R. C. A. M. Waardenburg, 1999 .

Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage

M. Bjornsti, R. C. A. M. Waardenburg, R. C. V. Waardenburg, 2005 .

ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin

S. Aller, J. Feduska, S. Cramer, 2014, Oncogene.

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood

J. Beijnen, M. Ravic, J. Schellens, 2003, Anti-cancer drugs.

Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

J. Schellens, D. Pluim, R. V. van Waardenburg, 1999, Cancer research.

DNA-based drug interactions of cisplatin.

J. Schellens, J. Beijnen, R. V. van Waardenburg, 2002, Cancer treatment reviews.

32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

J. Beijnen, J. Schellens, D. Pluim, 1999, Analytical biochemistry.